Sold as Ganite. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Gallium Nitrate (sold as Ganite), first approved Jan 17, 1991, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)Nontuberculous Mycobacterium Infection · Chris Goss | Phase 1 | Recruiting | Mar 3, 2020 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jan 17, 1991 | GaniteNDA 19961 · New molecular entity | Chapter 7 Trustee | 3 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
